Cold-fX

Cold-fX is a ginseng-derived natural health product that is widely used in Canada for the prevention and treatment of the common cold. It is manufactured by CV Technologies, a company based in Edmonton, Alberta.

History

Cold-fX was first introduced to the Canadian market in 1996 by CV Technologies, which is now known as Afrazen Biosciences. The product was developed by Jacqueline Shan, a scientist with a background in pharmacology and Traditional Chinese Medicine.

Composition

The active ingredient in Cold-fX is a patented extract of North American ginseng (Panax quinquefolius), known as CVT-E002. This extract is standardized to contain 80% poly-furanosyl-pyranosyl-saccharides, which are believed to have immune-boosting properties.

Clinical Evidence

Several clinical trials have been conducted to evaluate the efficacy of Cold-fX in preventing and treating the common cold. These studies have generally found that Cold-fX can reduce the frequency, severity, and duration of cold symptoms, although some researchers have questioned the quality of the evidence.

Controversies

In 2007, CV Technologies was criticized for making unsubstantiated claims about the effectiveness of Cold-fX. The company was also involved in a class-action lawsuit in 2012, which alleged that it had misled consumers about the product's ability to prevent colds.

See Also

• Ginseng
• Common cold
• Natural health product
• CV Technologies
• Jacqueline Shan

   This article is a medical stub. You can help WikiMD by expanding it!

   This article is a Canada-related stub. You can help WikiMD by expanding it!